FDA Approves Welireg Combined with Pembrolizumab for Kidney Cancer Treatment

The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) combined with pembrolizumab or Keytruda Qlex for adjuvant treatment of renal cell carcinoma with clear cell component in adults at intermediate-high or high risk of recurrence after surgery. This approval represents an important advancement in kidney cancer treatment, offering patients a dual immunotherapy approach to reduce the risk of cancer returning following nephrectomy or removal of metastatic lesions. The combination therapy targets different biological pathways to enhance cancer-fighting effectiveness. This FDA decision expands treatment options for patients with advanced kidney cancer who have undergone surgical intervention.